Buscar
Mostrando ítems 1-9 de 9
Immune profiling uncovers memory T-cell responses with a Th17 signature in cancer patients with previous SARS-CoV-2 infection followed by mRNA vaccination
(MDPI, 2022)
Artículo / Artikulua,
It is unclear whether patients with cancer present inherently impaired responses to COVID-19 and vaccination due to their treatments, neoplastic diseases or both. To address this question, immune profiling was performed ...
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
(MDPI, 2022)
Artículo / Artikulua,
PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic ...
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies
(Springer Nature, 2024)
Artículo / Artikulua,
Background: Previous studies have shown that functional systemic immunity is required for the efficacy of PD-1/PD-L1 blockade immunotherapies in cancer. Hence, systemic reprogramming of immunosuppressive dysfunctional ...
Clinical landscape of LAG-3-targeted therapy
(Elsevier, 2022)
Artículo / Artikulua,
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation ...
Understanding LAG-3 Signaling
(MDPI, 2021)
info:eu-repo/semantics/article,
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
(Springer Nature, 2021)
info:eu-repo/semantics/article,
Background: improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity ...
Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy
(EMBO Press, 2020)
info:eu-repo/semantics/article,
The search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful ...
Cutting-edge: preclinical and clinical development of the first approved LAG-3 inhibitor
(MDPI, 2022)
Artículo / Artikulua,
Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important ...
Cutting-edge CAR engineering: beyond T cells
(MDPI, 2022)
Artículo / Artikulua,
Chimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks ...